期刊
BLOOD
卷 118, 期 3, 页码 703-711出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-04-347039
关键词
-
类别
资金
- National Institutes of Health [RO1 CA76287, K08 CA095448, PO1 CA44991, R01 CA136639]
- Leukemia & Lymphoma Society
- Frederick Kullman and Penny E. Petersen Memorial Funds
- endowed Chair from James and Sherry Raisbeck
- FHCRC Experimental Histopathology Shared Resources
Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)-streptavidin (SA) conjugate and DOTA-biotin labeled with beta-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity. alpha-emitting radionuclides exhibit high cytotoxicity coupled with a short path length, potentially increasing the therapeutic index and making them an attractive alternative to beta-emitting radionuclides for patients with acute myeloid leukemia. Accordingly, we have used Bi-213 in mice with human leukemia xenografts. Results demonstrated excellent localization of Bi-213-DOTA-biotin to tumors with minimal uptake into normal organs. After 10 minutes, 4.5% +/- 1.1% of the injected dose of Bi-213 was delivered per gram of tumor. alpha-imaging demonstrated uniform radionuclide distribution within tumor tissue 45 minutes after Bi-213-DOTA-biotin injection. Radiation absorbed doses were similar to those observed using a beta-emitting radionuclide (Y-90) in the same model. We conducted therapy experiments in a xenograft model using a single-dose of Bi-213-DOTA-biotingiven 24 hours after anti-CD45 Ab-SA conjugate. Among mice treated with anti-CD45 Ab-SA conjugate followed by 800 mu Ci of Bi-213- or Y-90-DOTA-biotin, 80% and 20%, respectively, survived leukemia-free for more than 100 days with minimal toxicity. These data suggest that anti-CD45 PRIT using an alpha-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia. (Blood. 2011;118(3):703-711)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据